Medical Supply Chain Dominated by China
Excerpt: According to his recent Senate testimony, Scott Gottlieb, a physician who is also a former Trump administration Food and Drug Administration commissioner, detailed some of our strategic reliance on China for pharmaceuticals: “About 40 percent of generic drugs sold in the U.S. have only a single manufacturer. A significant supply chain disruption could cause shortages for some of many of these products. [In 2019], manufacturing of intermediate or finished goods in China, as well as pharmaceutical source material, accounted for 95 percent of U.S. imports of ibuprofen, 91 percent of U.S. imports of hydrocortisone, 70 percent of U.S. imports of acetaminophen, 40 to 45 percent of U.S. imports of penicillin, and 40 percent of U.S. imports of heparin, according to the Commerce Department. In total, 80 percent of the U.S. supply of antibiotics are made in China.” Oh, and by the way, Gottlieb notes, “When it comes to starting material for the manufacture of pharmaceutical ingredients, a lot of this production is centered in China’s Hubei Provence, the epicenter of coronavirus.” This isn’t the free market at work. It’s the result of Beijing’s typical and strategic market manipulation, including underselling global competitors to put them out of business and enable China’s market domination.